Wednesday, January 04, 2017 11:11:26 AM
About Q BioMed
Q BioMed logoQ BioMed, Inc., formerly ISMO Tech Solutions, Inc., is a biomedical acceleration and development company. The Company is focused on licensing, acquiring and providing strategic resources to life sciences and healthcare companies. The Company intends to acquire multiple assets over time and across a spectrum of healthcare related products, companies and sectors. The Company intends to develop these assets to provide returns through organic growth, out-licensing, sale or spin-off into new public companies. The Company holds license for a generic drug, Strontium Chloride (SR89). SR89 is a radiopharmaceutical agent and indicated for the treatment of pain associated with metastatic bone cancer. Its asset, MAN-01, is indicated for the treatment of glaucoma. MAN-01 is in pre-clinical stage. The Company is assessing multiple biomedical assets in various areas of healthcare and drug development. It is pursuing a pipeline of therapeutics, diagnostics and orphan drug candidates.
Industry, Sector and Symbol: •Sector: N/A
•Industry: N/A
•Sub-Industry: N/A
•Exchange: NASDAQ
•Symbol: QBIO
•CUSIP:
Key Metrics:
•Previous Close: $5.94
•50 Day Moving Average: $4.07
•200 Day Moving Average: $3.27
•52-Week Range: $1.26 - $8.00
•Trailing P/E Ratio: N/A
•P/E Growth: 0.00
•Market Cap: $70.86M
Additional Links:
•View QBIO on Google Finance
•View QBIO on Yahoo Finance
•View QBIO's Company Profile on Reuters
•Search for Q BioMed Inc on Google
•Much success can be attributed to inactivity. Most investors cannot resist the temptation to constantly buy and sell.
•Only buy something that you’d be perfectly happy to hold if the market shut down for 10 years.
Warren Buffett
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM